Fenofibrate/simvastatin

From Wikipedia, the free encyclopedia

Fenofibrate/simvastatin
Combination of
FenofibrateFibrate
SimvastatinStatin
Clinical data
Trade namesCholib
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • EU: Rx-only [1]
Identifiers
CAS Number
KEGG

Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]

It was approved for use in the European Union in August 2013.[1]

Medical uses[edit]

Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]

Adverse effects[edit]

References[edit]

  1. ^ a b c d e "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading[edit]

External links[edit]

  • "Fenofibrate". Drug Information Portal. U.S. National Library of Medicine.
  • "Simvastatin". Drug Information Portal. U.S. National Library of Medicine.